UK firm seeks allies for joint drug research

Image
P B Jayakumar Mumbai
Last Updated : Jan 29 2013 | 2:16 AM IST

As part of its foray into India, William Harvey Research (WHRL) - the UK-based contract research organisation (CRO) and part of the renowned William Harvey Research Institute - is in discussions with three leading Indian pharmaceutical companies for joint drug research and collaborations.

“We are looking at drug research alliances in India and talking to three major Indian companies that are developing new drugs. However, it is too early to name the companies and the nature of discussions,” said Christoph Theimermann, chief executive officer, WHRL.

WHRL was founded in 1990 by Nobel laureate Sir John Vane to fund the research works at William Harvey Research Institute, one of the leading centres in the world for pharmacological research.

The company specialises in pre-clinical drug development in the areas of inflammatory and cardio vascular diseases.

In the past, the CRO has conducted over 80 drug discovery programmes allying with leading multi-national companies, such as Glaxosmithkline (GSK), Eli Lilly and the like, for the same.

Christoph Theimermann, now in India for launching a collaborative academic programme with the Mumbai-based Clinical Research Education and Management Academy (Crema), said the new drug research programmes undertaken by many of the Indian companies have the potential to come out with blockbuster drugs.

Chandan Alam, director, academic collaborations at William Harvey Research Institute, said, “The alliance with WHRL would initially be for student and faculty exchanges and for imparting training to 500-odd students with Crema.

India’s CRO sector is expected to become a $1-billion industry by 2010 from $300-350 million estimated currently, consisting of about 280 CROs. A McKinsey study estimates that the industry would require about 50,000 professional investigators and professionals by 2015.

According to Ramananda Nadig, president, Crema, there are about ten training centres in the country for contract research, all in the private sector, churning out 3,000 professionals every year.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 02 2008 | 12:00 AM IST

Next Story